Oncosec Medical Incorporated (ONCS) Return on Equity ROE from the second quarter 2023 to second quarter 2022 and annually, average high and low, overall ranking from Jan 31 2023 to Jan 31 2022 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Oncosec Medical Incorporated  (NASDAQ: ONCS)

Oncosec Medical Incorporated's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Oncosec Medical Incorporated in the second quarter 2023?
Oncosec Medical Incorporated recorded a cumulative net loss of $-29 million during 12 months ending in the second quarter 2023, resulting in a negative return on equity (ROE) of -868.37%.

Within the Major Pharmaceutical Preparations industry 495 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2023 from 0 to 4786.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jan 31 2023)
II. Quarter		 (Oct 31 2022)
I. Quarter		 (Jul 31 2022)
IV. Quarter		 (Apr 30 2022)
III. Quarter		 (Jan 31 2022)
II. Quarter
Y / Y Equity Change - - -83.93 % -70.71 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -29 -32 -34 -38 -41
Return On Equity (TTM) -868.37 % -334.03 % -199.3 % -150.2 % -122.18 %
ONCS's Total Ranking # 4786 # 0 # 0 # 0 # 0
Equity (TTM) in Millions -5 -1 6 14 20
Seq. Equity Change - - -55.95 % -29.91 % -31.15 %
Seq. Net Income Change - - - - -

Back to ONCS Management Effectiveness >> ONCS's 5 Years Annual ROE >> Compare ONCS ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 496
Sector # 1004
Overall # 4786

Return On Equity Statistics
High Average Low
-102.83 %
-219.17 %
-868.37 %
(Oct 31 2021)   (Jan 31 2023)





ONCS Annual Return On Equity (Jul 31 2022)
2022		 (Jul 31 2021)
2021		 (Jul 31 2020)
2020		 (Jul 31 2019)
2019		 (Jul 31 2018)
2018
Total Equity in Millions 6 38 14 24 23
Y / Y Equity Change -83.93 % 174.51 % -42.87 % 5.91 % 114.33 %
Net Income in Millions -34 -45 -42 -30 -39
Y / Y Net Income Change - - - - -
Return On Equity -558.64 % -118.63 % -304.63 % -124.7 % -170.72 %

Back to ONCS Management Effectiveness >> ONCS's 5 Years Annual ROE >> Compare ONCS ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
ONCS's' Return on Equity at Yahoo Finance
ONCS's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for ONCS's Competitors
Subscribers only: Roe for Oncosec Medical Incorporated's Suppliers
Subscribers only: Return On Equity for ONCS's Customers




Companies with similar Return On Equity at Jan 31 2023, within Healthcare Sector ROE

Date modified: 2026-09-08T15:10:51+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.